MangoceuticalsMGRX 26 Days Payable is 1,107.87 as of Mar. 2026, which is 19% above its 10-year median of 934.45. GuruFocus rates MGRX with a GF Score™ of 26/100 and a GF Value™ of $0.31 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 607 Healthcare Providers & Services companies, Mangoceuticals ranks better than 96.87% on this metric.
The historical rank and industry rank for Mangoceuticals's Days Payable or its related term are showing as below:
MGRX'
s Days Payable Range Over the Past 10 Years
Min: 106.81 Med: 934.45 Max: 3102.5
Current: 1267.31
During the past 5 years, Mangoceuticals's highest Days Payable was 3102.50. The lowest was 106.81. And the median was 934.45.
MGRX's Days Payable is ranked better than 96.87% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 58.16
vs MGRX: 1267.31
Mangoceuticals's Days Payable
declined
from Mar. 2025 (1,957.02) to Mar. 2026 (1,107.87).
It may suggest that Mangoceuticalsaccelerated paying its suppliers.
Mangoceuticals Days Payable Related Terms
Mangoceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Mangoceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Mangoceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangoceuticals Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Mangoceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mangoceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mangoceuticals (MGRX) has a Days Payable of 1,107.87 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mangoceuticals and its competitors. This is 19% above median its historical median of 934.45. Over the past decade, Mangoceuticals' Days Payable has ranged from 106.81 to 3,102.50. According to the industry distribution chart, Mangoceuticals ranks #19 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 3.1%.
Is Mangoceuticals' Days Payable too high?
Mangoceuticals' current Days Payable of 1,107.87 is 19% above median its 10-year median of 934.45. Over the past 10 years, this metric has ranged from a low of 106.81 to a high of 3,102.50. The Healthcare Providers & Services industry median Days Payable is 58.16. Mangoceuticals' value of 1,107.87 is 1804.9% above this industry median. Based on the distribution chart, Mangoceuticals ranks #19 out of 607 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mangoceuticals has a GF Score™ of 26/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mangoceuticals' Days Payable compare to WLSS and ACON?
According to the Healthcare Providers & Services industry distribution chart, Mangoceuticals ranks #19 out of 607 companies for Days Payable. This places Mangoceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 58.16. Mangoceuticals' value of 1,107.87 is 1804.9% above this benchmark. Historically, Mangoceuticals' own Days Payable has ranged from 106.81 to 3,102.50 over the past decade. While the company's 10-year median is 934.45 vs. the industry median of 58.16, Mangoceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.16, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mangoceuticals's current Days Payable of 1,107.87 is 1804.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mangoceuticals and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangoceuticals's current Days Payable is 1,107.87, which is 19% above median its own 10-year median of 934.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangoceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mangoceuticals (MGRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.31, compared to a current price of $0.38 — trading 22.6% above its estimated fair value. The current Days Payable is 1,107.87, which is 19% above median its 10-year median of 934.45 and 1804.9% above the Healthcare Providers & Services industry median of 58.16. Mangoceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mangoceuticals (MGRX), the current Days Payable is 1,107.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangoceuticals (MGRX) Overvalued in 2026?
Based on GuruFocus' analysis, Mangoceuticals stock appears to be overvalued.
The current stock price of $0.38 is trading 22.6% above its estimated GF Value™ of $0.31.
GuruFocus considers Mangoceuticals to be Modestly Overvalued.
Key valuation signals for MGRX:
Days Payable: 1,107.87 (19% above median its 10-year median of 934.45)
GF Value™: $0.31 vs. price of $0.38 (22.6% above fair value)
Industry Position: 1804.9% above the Healthcare Providers & Services median (#19 of 607)
No single metric tells the full story. See the MGRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
26GF Score
Get the complete analysis for MGRX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGRX has been successfully added to your 
